Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
600267.SS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
+33%
0.2
vs 0.15
Q3.23
+200%
0.03
vs 0.01
Q4.23
N/A
-0.47
vs 0.14
Q1.24
N/A
-0.47
vs 0.16
Q2.24
-20%
0.16
vs 0.2
Q3.24
+133%
0.07
vs 0.03
Q4.24
+117%
0.08
vs -0.47
Q1.25
+136%
0.17
vs -0.47
Q2.25
N/A
-0.05
vs 0.16
Q3.25
-57%
0.03
vs 0.07
Sales Growth
YoY
Current
Estimates
Q2.23
+9%
3B vs 2.8B
Q3.23
-12%
2.6B vs 3B
Q4.23
-49%
1.7B vs 3.3B
Q1.24
-11%
2.7B vs 3.1B
Q2.24
-17%
2.5B vs 3B
Q3.24
0%
2.6B vs 2.6B
Q4.24
+14%
1.9B vs 1.7B
Q1.25
-3%
2.6B vs 2.7B
Q2.25
+4%
2.6B vs 2.5B
Q3.25
-2%
2.6B vs 2.6B
Return on Equity
QoQ
Q2.23
+2%
0.02
vs 0.03
Q3.23
+0%
0
vs 0.02
Q4.23
-7%
-0.07
vs 0
Q1.24
+3%
0.03
vs -0.07
Q2.24
+2%
0.02
vs 0.03
Q3.24
+1%
0.01
vs 0.02
Q4.24
+1%
0.01
vs 0.01
Q1.25
+2%
0.02
vs 0.01
Institutionnal Ownership
Forecast
378%2026-Revenue
353%2026-EPS
619%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
600267.SS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.
SHH
0.46Â ( 3.84%)
Relative Strenght
Volume Buzz
345%
Earning Acce
Yes
Dist 52w H.
5%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 600267.SS compares to sector?